Cosmetic Results With Tissue Adhesive vs. Subdermal Sutures in Cesarean Section
Launched by RICARDO A GUTIERREZ RAMIREZ, MD, MSC, FACOG · Dec 30, 2024
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of tissue adhesives, a type of medical glue, compared to traditional stitches for closing wounds after a cesarean section. The goal is to see if using these adhesives can lead to better-looking scars and fewer complications after surgery. Researchers will test different ways to apply the glue while keeping the total amount the same, to find out if the method affects the results.
To participate in this study, women who are 37 weeks pregnant and scheduled for an elective cesarean section at the Hospital Materno Infantil in Tegucigalpa, Honduras, may be eligible. Participants should be literate and have a body mass index under 30. They must also have a way to communicate for follow-up after the surgery. Those with certain health issues, such as diabetes or severe pregnancy complications, will not be able to participate. If you join the study, you can expect to be monitored during your recovery, and your experiences will help improve cesarean wound care for future patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Submission of a signed and dated informed consent form.
- • Declared willingness to comply with all study procedures and availability for the duration of the study.
- • Pregnant patient at 37 or more weeks gestation, scheduled for elective cesarean section at the Hospital Materno Infantil.
- • Cesarean section performed in the Maternity and Children's Hospital, operating room.
- • Literate patient, able to understand and respond to the study questions, with body mass index less than 30.
- • Possess cell phone or other means of communication to facilitate postoperative follow-up.
- • Residing in the city of Tegucigalpa, Honduras, to ensure accessibility to scheduled follow-up visits.
- Exclusion Criteria:
- • Patients under 18 years of age.
- • Patients with diagnosed psychiatric illnesses that may interfere with their ability to give informed consent or follow the study protocol.
- • Pregnant patients with complications that may affect the healing process or increase the risk of postoperative complications, such as severe preeclampsia.
- • Diabetes.
- • Collagen diseases.
- • Autoimmune diseases (rheumatoid arthritis, Crohn's disease).
- • Vascular diseases (vasculitis).
- • Coagulation disorders (thrombophilia).
- • Pregnant patients with premature rupture of membranes, since this may influence the choice of timing and method of cesarean section.
- • Pregnant patients diagnosed with chorioamnionitis, which represents an increased risk of postoperative infection.
- • Pregnant patients diagnosed with acute abdomen, which may require emergency surgical management that is not compatible with standard cesarean section procedures.
- • Pregnant patients with multiple pregnancies, since this could complicate the cesarean section procedure and affect the results of the study.
- • Presence of major fetal malformations that may require additional interventions at birth.
- • Fetal stillbirth
About Ricardo A Gutierrez Ramirez, Md, Msc, Facog
Dr. Ricardo A. Gutierrez Ramirez, MD, MSc, FACOG, is a distinguished clinical trial sponsor and expert in the field of obstetrics and gynecology. With advanced degrees and board certification, he brings a wealth of knowledge and experience in conducting clinical research aimed at improving women's health outcomes. Dr. Gutierrez Ramirez is committed to advancing medical science through rigorous study design, ethical practices, and innovative methodologies, ensuring high-quality data that contribute to the development of effective treatments and interventions. His dedication to patient safety and scientific integrity positions him as a leading figure in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tegucigalpa, Fm, Honduras
Patients applied
Trial Officials
Ricardo A. Gutierrez Ramirez, MD, MSc
Study Director
Universidad Nacional Autonoma de Honduras
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported